Skip to content
Market Spectator

Market Spectator

Primary Menu
  • Business
  • Domestic
  • Economy
  • Politics
  • Top News
  • Newsletters
Live
  • Home
  • 2026
  • November
  • 17
  • Tyson’s Beef Losses Are Shrinking. The Stock Already Priced It.
  • Politics

Tyson’s Beef Losses Are Shrinking. The Stock Already Priced It.

A $654 million beef deficit is heading toward breakeven in fiscal 2027. JPMorgan just said the rally has run its course.
Market Spectator November 17, 2026 3 minutes read
f8a74c82-6839-4612-9dab-7df2a45449fd

Tyson Foods spent fiscal 2026 generating strong returns in chicken while absorbing one of the worst beef cycles in its history. The stock rewarded patient holders with a 23% run over two months. Now comes the harder question: how much recovery is already in the price?

The beef problem was severe. Tyson’s beef segment lost $654 million in fiscal 2026 on sales of about $21.3 billion, as tight cattle supplies drove a 12.2% decline in volume. A non-cash inventory adjustment added another $80 million in the year. The losses did not come from execution failure alone. Volatile cattle prices and a severe cattle shortage compressed margins across the whole industry.

Chicken was the counterweight. The chicken segment delivered $1.86 billion in full-year operating income at a 10.7% margin, with volume growing 2.1%, marking eight consecutive quarters of volume growth. That consistency matters. It tells you the operational improvements in chicken are structural, not cyclical.

The 2027 bet is entirely about beef. The fiscal 2027 adjusted beef outlook ranges from a $300 million loss to $100 million of income, compared with a $654 million adjusted loss in fiscal 2026. That is a potential $750 million swing at the top end. The bridge has two legs: the company has rationalized its beef processing footprint, formed a new partnership with Allied Beef, and benefited from the reopening of the Mexican border for live cattle imports. The reopening of the second shift at the Amarillo beef facility is expected to be fully operational by summer 2027.

Heifer retention rates continue to increase, and management has said it believes beef cattle herd rebuilding is underway. That is a supply-side catalyst with a multi-year lag. It does not arrive in one quarter.

Where JPMorgan draws the line. Analyst Thomas Palmer noted the shares rose 9% following the Q4 report and gained 23% over the past two months. The stock currently trades at a P/E of 38.92, suggesting a premium valuation following the rally. JPMorgan downgraded Tyson from Overweight to Neutral while raising its price target from $63 to $65, implying about 2% upside from the prior close. The bank had upgraded shares in September when TSN was trading near book value. The logic then was asymmetric. The logic now is symmetric at best.

Not everyone agrees. Piper Sandler maintained an Overweight rating and raised its price target from $56 to $72. The divergence between the two firms captures the real debate: is a path to beef breakeven worth paying a near-40x multiple for a protein processor?

Tight cattle supplies, higher feed costs, livestock disease, and further legal accruals remain key risks to the fiscal 2027 outlook. The recovery story is real. The timing and magnitude of that recovery, spread across a wide guidance range, is not.

Post navigation

Previous: Good News From American Consumers Could Hurt Stocks Today
Next: CG Oncology’s Trial Win Is Real. Buying the Stock Now Is Different.

Related Stories

b1389184-c69e-4bcd-85e1-2b50e4c16184
  • Politics

Klarna’s Margins Are Outrunning Its Losses

Market Spectator November 18, 2026
928de7d2-8897-404a-9cfe-6ef8449e1e31
  • Politics

Roche Gets an FDA Approval for a Rare Kidney Disease

Market Spectator November 16, 2026
23290d3b-9fae-4921-a167-e0c9cc545efa
  • Politics

Rheinmetall Is Down 50% This Year. Peace Talks Complicate It.

Market Spectator November 13, 2026

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Recent Posts

  • Klarna’s Margins Are Outrunning Its Losses
  • CG Oncology’s Trial Win Is Real. Buying the Stock Now Is Different.
  • Tyson’s Beef Losses Are Shrinking. The Stock Already Priced It.
  • Good News From American Consumers Could Hurt Stocks Today
  • Lowe’s Reports Tomorrow. The Stock Is 27% Off Its Low.
  • Roche Gets an FDA Approval for a Rare Kidney Disease
  • Brent Fell After Iran Hit Bahrain. That Tells You Everything.

Categories

  • Business
  • Economy
  • Money
  • Newsletters
  • Politics
  • Top News

You may have missed

b1389184-c69e-4bcd-85e1-2b50e4c16184
  • Politics

Klarna’s Margins Are Outrunning Its Losses

Market Spectator November 18, 2026
c59eafff-cbd2-44f9-ad1d-cf51f1a469d3
  • Top News

CG Oncology’s Trial Win Is Real. Buying the Stock Now Is Different.

Market Spectator November 18, 2026
f8a74c82-6839-4612-9dab-7df2a45449fd
  • Politics

Tyson’s Beef Losses Are Shrinking. The Stock Already Priced It.

Market Spectator November 17, 2026
56e5c18c-a867-4581-923b-4d71ffc87e28
  • Newsletters

Good News From American Consumers Could Hurt Stocks Today

Market Spectator November 17, 2026
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms of Service/Use Agreement
  • Contact Us
Copyright 2026 © All rights reserved | Market Spectator | marketspectator.com SITE_OK